OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.
OSE IMMUNOTHERAPEUTICS
Industry:
Biotechnology Medical Medical Device Pharmaceutical
Founded:
2012-01-01
Address:
Nantes, Pays De La Loire, France
Country:
France
Website Url:
http://www.ose-immuno.com
Total Employee:
11+
Status:
Active
Contact:
+33143297857
Total Funding:
45.35 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Sitelinks Search Box Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
Genmedica Therapeutics
Genmedica Therapeutics is a development-stage biotechnology company focused on type 2 diabetes.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Osteal Therapeutics
Osteal Therapeutics is a clinical stage specialty pharmaceutical company developing novel treatments for orthopedic infections.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Oryl Photonics
Oryl Photonics is an innovation-focused photonics company.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Scandinavian Real Hearts
Scandinavian Real Hearts is a medical technology company that develops an artificial heart.
Current Advisors List
Board_member
2022-01-01
Current Employees Featured
Anne-Laure Autret-Cornet Chief Financial Officer @ OSE Immunotherapeutics
Chief Financial Officer
Nicolas Poirier Chief Scientific Officer @ OSE Immunotherapeutics
Chief Scientific Officer
Maryvonne Hiance Vice Chairman and Director of Public Affairs @ OSE Immunotherapeutics
Vice Chairman and Director of Public Affairs
Emile Loria Chairman @ OSE Immunotherapeutics
Chairman
Frederique Corallo Chief Medical Officer @ OSE Immunotherapeutics
Chief Medical Officer
Alexis Vandier Chief Executive Officer @ OSE Immunotherapeutics
Chief Executive Officer
2022-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-02-24 | Effimune SAS | Effimune SAS acquired by OSE Immunotherapeutics | N/A |
Investors List
European Investment Bank
European Investment Bank investment in Debt Financing - OSE Immunotherapeutics
Bpifrance
Bpifrance investment in Grant - OSE Immunotherapeutics
Bpifrance
Bpifrance investment in Grant - OSE Immunotherapeutics
Key Employee Changes
Official Site Inspections
http://www.ose-immuno.com Semrush global rank: 1.81 M Semrush visits lastest month: 12.57 K
- Host name: cluster024.hosting.ovh.net
- IP address: 188.165.61.82
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "OSE Immunotherapeutics"
Ose Immuno
OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO ... Email : contact@ose-immuno.com. Bureaux de Paris. 10, place de …See details»
Our Company - Ose Immunotherapeutics - Société de …
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20 th Congress of ECCO ... Email : contact@ose-immuno.com. Paris …See details»
OSE Immunotherapeutics - Crunchbase Company …
OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for. immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, …See details»
OSE Immunotherapeutics Company Description - Stock Analysis
Jan 3, 2025 Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; …See details»
OSE Immunotherapeutics - LinkedIn
OSE Immunotherapeutics Biotechnology Research NANTES, PAYS DE LA LOIRE 16,742 followers Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for PatientsSee details»
OSE Immunotherapeutics - Craft
Oct 29, 2024 OSE Immunotherapeutics has 5 employees across 2 locations and €2.23 m in annual revenue in FY 2023. ... company that focuses on the development of immunotherapies …See details»
OSE Immunotherapeutics Provides Business and Corporate Update
NANTES, France, May 30, 2024 – 6:15pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided business and corporate update after …See details»
Société OSE Immunotherapeutics - Zonebourse.com
Jan 3, 2025 OSE Immunotherapeutics: Présentation de la société OSE Immunotherapeutics, actionnaires, dirigeants, description métier, rating financiers, communiqués officiels ...See details»
OSE Immunotherapeutics Strengthens Leadership and Executive
Dec 3, 2024 OSE Immunotherapeutics Strengthens Leadership and Executive Committee . NANTES, France, December 2, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: ...See details»
Partnership for first-in-class cancer and CRM …
May 22, 2024 Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced a major expansion of their partnership. Two new projects to …See details»
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as …
15 hours ago OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA …See details»
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as …
14 hours ago OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet …See details»
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as …
15 hours ago NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Dr. Sonya …See details»
Investors - Ose Immunotherapeutics - Société de biotechnologie …
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in ... All events . 19/02/2025. 20th Congress of European Crohn’s and Colitis Organization (ECCO) …See details»
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab …
Dec 18, 2024 OSE Immunotherapeutics. A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for …See details»
OSE Immuno renforce son équipe - Boursier.com
14 hours ago Sonya Montgomery fera partie du Comité exécutif d'OSE Immuno dans le cadre d'une approche stratégique visant à renforcer les capacités de développement de la société.See details»
OSE Immunotherapeutics annonce la nomination du Dr. Sonya
15 hours ago OSE Immunotherapeutics est une société de biotechnologie qui développe des produits first-in-class en immuno-oncologie (IO) et immuno-inflammation (I&I) pour répondre …See details»
OSE Immuno: recruits its new Chief Development Officer
14 hours ago OSE Immuno: recruits its new Chief Development Officer January 13, 2025 at 12:16 pm EST Share OSE Immunotherapeutics announces the appointment of Dr. Sonya …See details»
20ème Congrès de l’ECCO (European Crohn’s and Colitis …
20ème Congrès de l’ECCO (European Crohn’s and Colitis Organization) 19-22 février 2025, Berlin. Siège social. 22, boulevard Benoni Goulin 44200 Nantes – France. Tel : +33 (0)2 28 29 …See details»
OSE Immuno: recrute son nouveau 'Chief Development Officer'
14 hours ago (CercleFinance.com) - OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer. Sonya Montgomery fera partie du …See details»